MIRAbenzinga

EXCLUSIVE: MIRA Pharmaceuticals Tells Benzinga Co. Reports No Brain Toxicity In FDA-Required Study Of Ketamir-2, Says Confirming Absence Of Ketamine-Linked Neurotoxicity

Summary

No summary available.

Original Article

Read the full article from the original source for complete details and context.

Read Full Article

Article published on May 6, 2025 by benzinga

    EXCLUSIVE: MIRA Pharmaceuticals Tells Benzinga Co. Reports No Brain Toxicity In FDA-Required Study Of Ketamir-2, Says Confirming Absence Of Ketamine-Linked Neurotoxicity | MIRA Stock News | Candlesense